Is Stryker (SYK) Stock Rich Or Reasonable After Its Robotics Launch?

Stryker stock presents a split picture right now. The Discounted Cash Flow (DCF) intrinsic value estimate points to about 15.0% upside from the current share price, while traditional earnings multiples make the stock look expensive and the broader valuation checks are cautious.

• Over the past 5 years Stryker has returned 36.2%, which suggests the stock has already delivered a solid long term outcome for shareholders.
• The launch of the Mako RPS handheld robotic system may support expectations for future orthopedic procedure volumes, while concerns about hospital capital spending and competitive pressure on pricing and margins remain a clear risk for the valuation case.
• Stryker currently passes only 1 of 6 valuation checks, which leans more toward a stock that is not an obvious bargain on the broad metrics.

The issue now is whether investors should treat the DCF implied discount as a meaningful margin of safety or give more weight to the richer multiples and low value score when assessing Stryker.

Stryker delivered -12.6% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Is Stryker a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Stryker might be worth based on the cash it is expected to generate for shareholders. For Stryker, the latest twelve month free cash flow is about $4.6b, and the cash flow projections used in the 2 Stage Free Cash Flow to Equity model assume growing cash flows rather than a contraction.

On these assumptions, the DCF model points to an intrinsic value of about $408 per share, which sits around 15.0% above the current share price. The recent launch of the Mako RPS handheld robotic system helps explain why some investors are still willing to pay a premium for growth, even though the valuation model suggests the market price is below the level supported by the modeled cash flows.

Overall, the DCF workup indicates that Stryker stock appears undervalued relative to the cash flows that are currently incorporated into the model.

Our Discounted Cash Flow (DCF) analysis suggests Stryker is undervalued by 15.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Stryker.

Has Stryker Run Too Far on Earnings?

The P/E ratio suits Stryker because earnings are a key driver for mature medical equipment businesses that still invest heavily in new products. Stryker currently trades on a P/E of about 39.8x, compared with a Medical Equipment industry average near 28.0x and a peer average around 29.4x. That puts the stock at a clear premium to both its sector and close comparables.

The fair P/E ratio for Stryker is estimated at roughly 35.0x, based on its mix of growth prospects, profitability, size and risk profile. The gap between the current 39.8x and this fair level suggests investors are paying up for the story, including the Mako robotics portfolio and other growth projects, even as hospital spending and competition remain watch points.

On the P/E multiple, Stryker stock appears overvalued relative to both its industry and the fair ratio implied by its fundamentals.

See what the numbers say about this price — find out in our valuation breakdown.

The Stryker Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Stryker valuation puzzle leaves off by spelling out which paths for Stryker's growth, margins and earnings would need to unfold for the stock to be worth materially more or materially less than today's price. Each narrative ties a fair value to a specific storyline about Stryker's potential catalysts and risks, so you can track over time which version of events appears to be taking shape on the Community page.

Add your voice to the Simply Wall St community with a Narrative on Stryker that lays out a number driven view on whether launches like the Mako RPS handheld robotic system and concerns about hospital spending justify today's valuation. Share the key drivers you think matter most for Stryker's growth, margins and execution, and then track how your thesis holds up as new results and updates arrive.

Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) intrinsic value estimate points to Stryker stock trading at a discount, while the market multiple view flags it as overvalued. That split reflects a cash flow model that is comfortable with the funding needs and capital intensity of Stryker's growth plans, in contrast to a P/E that already incorporates strong sentiment and high expectations for that growth to show up in earnings. Broader valuation checks remain weak, so the key question is whether Stryker can sustain attractive growth and margins without compressing returns, or whether the current premium P/E leaves limited room for disappointment.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com